-
For today's top Money video click here - News Providers
- Associated Press
- Barron's
- bizjournals.com
- Briefing.com
- BusinessWeek
- Business Wire
- Forbes
- GlobeNewswire
- InvestorPlace
- MarketWatch
- Market Wire
- Minyanville
- Motley Fool
- MSNBC
- PRNewswire
- Thomson Reuters
- TheStreet.com
- Wall Street Journal
- News by Topic
- Companies
- Economy
- Industry
- Stock Market
- Commentary
- This Week
- Index
- MSN Money Experts
- Jim Jubak
- Jon Markman
- Liz Pulliam Weston
- MP Dunleavey
- More Experts
M.D. Anderson joins Stemline in leukemia drug trialsNovember 30, 2009 10:57 AM ETThe University of Texas M.D. Anderson Cancer Center is participating in a clinical trial with Stemline Therapeutics Inc. to test a leukemia drug. The Houston cancer center and New York biotechnology company are performing Phase 1 and 2 clinical trials of the drug SL-401 in patients with acute myeloid leukemia and myelodysplastic syndrome. SL-401 is intended to target the interleukin-3 receptor, a molecule found on cells, which is expressed on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. Copyright 2009 bizjournals.com
|
E-mail this article
Print-friendly version
Discuss this article
- Data providers
- Copyright © 2010 Thomson Reuters. Click for Restrictions.
- Quotes supplied by Interactive Data Real-Time Services.